Furthermore, tumor size decrease is significantly obvious when the combination of anti-PD-1 with NF-κB inhibition compared with anti-PD-1 therapy alone [152], suggesting that the optimal function of PD-1 suppressor demands prevention of NF-κB activity. Here, NFKB1 is linked to neoplasm.